Show simple item record

dc.contributor.authorCOVID-19 Evidence Review Group
dc.contributor.authorNational Centre for Pharmacoeconomics
dc.contributor.authorMedicines Management Programme
dc.date.accessioned2020-04-14T12:10:08Z
dc.date.available2020-04-14T12:10:08Z
dc.date.issued2020-03-24
dc.identifier.urihttp://hdl.handle.net/10147/627490
dc.descriptionOur review finds that the evidence on comparative efficacy is insufficient to conclude whether combination therapy is more beneficial than hydroxychloroquine alone. Importantly each of these drugs alone are known to prolong QT interval and the more serious ventricular arrhythmia, Torsades de Pointes has also been reported.en_US
dc.language.isoenen_US
dc.publisherHealth Service Executiveen_US
dc.subjectCORONAVIRUSen_US
dc.subjectCOVID-19en_US
dc.subjectDRUG THERAPYen_US
dc.subjectPATIENT SAFETYen_US
dc.titleHydroxychloroquine and azithromycin combination therapy for COVID-19en_US
dc.typeReporten_US
refterms.dateFOA2020-04-14T12:10:08Z


Files in this item

Thumbnail
Name:
hydroxychloroquine-and-azithro ...
Size:
275.8Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record